Core Viewpoint - Novo Nordisk is currently undervalued despite a significant decline in stock price and weak guidance for 2026, presenting a potential opportunity for contrarian dividend investors [1]. Group 1: Company Challenges - Novo Nordisk has faced challenges in the GLP-1 market, particularly due to inability to meet demand and competition from Eli Lilly's more effective drugs [2][5]. - The company has provided weak guidance for 2026, anticipating a decline in revenue and earnings, partly due to a drug pricing agreement with the U.S. government [5]. Group 2: Competitive Position - Novo Nordisk was the first to market a pill version of its GLP-1 drug, which may help regain market share before Eli Lilly's pill launch, as consumers generally prefer pills over injections [6]. - The company is developing an updated version of its GLP-1 drug to enhance competitiveness against Eli Lilly and is adopting a more aggressive stance against generic competitors [7]. Group 3: Financial Metrics - Novo Nordisk's price-to-earnings ratio stands at 13.5, significantly lower than Eli Lilly's 45, indicating a potentially attractive valuation [8]. - The company offers a dividend yield of 3.7%, with a payout ratio of approximately 40%, suggesting strong support for its dividend [8].